Gynecologic Oncology

A prospective observational screening study has concluded a cytology dual-stain (DS) biomarker effectively triages women who test positive for primary human papillomavirus (HPV) and are at higher risk of developing cervical cancer, irrespective of the HPV genotype.

Human papillomavirus (HPV) vaccination has significantly decreased the incidence and mortality of cervical cancer in girls and women between the ages of 15 and 24, according to a research letter in JAMA Pediatrics.

The vaccine, which protects patients from seven different strains related to HPV-related cancers, may be considered part of routine oncology care for survivors.

Dr. Don S. Dizon discusses how cancer centers can be more inclusive to the LGBTQ+ community, from the naming of the institutions to the types of magazines found in the waiting rooms.

Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.

The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.

A recent study suggests that unconscious or implicit bias may exist when it comes to physicians referring African American patients with breast cancer for genetic counseling and testing.

The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

The FDA has granted a fast track designation to the interleukin-2 variant immunotherapy nemvaleukin alfa for use in combination with pembrolizumab in the treatment of patients with platinum-resistant ovarian cancer.

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

As we move beyond COVID-19, the healthcare industry is just beginning to uncover the impact of delayed cancer screenings and care on oncology outcomes.

Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.

The FDA has granted priority review to a supplemental biologics license application for the use of cemiplimab-rwlc in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on, or after, chemotherapy.

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.

In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.

Results of a phase 2 study demonstrate that the anti-programmed death-1 (PD-1) antibody balstilimab from Agenus Inc. provides meaningful and durable clinical activity in patients with previously treated, recurrent/metastatic cervical cancer.

The official declaration means more funding for research initiatives.

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

The results, according to the study authors, demonstrate that screening the general population for tubal and ovarian cancer each year does not result in a survival benefit.

The American College of Obstetricians and Gynecologists (ACOG) recently published an updated committee opinion regarding morcellation of presumed uterine leiomyoma. Here are the key points.

We hear from Christine Isaacs, MD about the new ASCCP guidelines and what they mean for ob/gyns.

The unmet need for personalized follow-up care due to a wide variety of health burdens after treatment needs to be addressed.

For cervical cancer screening, human papillomavirus (HPV)–based screening modalities detect significantly more abnormal cervical cells than traditional liquid-based cytology (LBC) approaches, according to a study in JAMA Network Open.